Meyahealth
HomeGeneticsGenePNPO gene
Back to Gene
PNPO gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

PNPO gene

The PNPO gene is responsible for creating an enzyme that metabolizes vitamin B6 into its active form, which is critical for brain function and neurotransmitter signaling.

Normal Function

The PNPO gene provides instructions for producing the enzyme pyridox(am)ine 5'-phosphate oxidase. This enzyme is essential for the metabolism of vitamin B6. It chemically modifies pyridoxine and pyridoxamine—forms of vitamin B6 found in food—into pyridoxal 5'-phosphate (PLP). PLP is the active form of vitamin B6 and is required for protein metabolism and the processing of neurotransmitters, which are chemicals that transmit signals in the brain.

Health Conditions Related to Genetic Changes

Pyridoxal phosphate-responsive seizures

Variants in the PNPO gene cause pyridoxal phosphate-responsive seizures, also known as PNPO deficiency.

  • Clinical Presentation: Affected individuals typically develop seizures shortly after birth.
  • Mechanism: Mutations change the amino acid structure of the enzyme, impairing its ability to metabolize vitamin B6 into PLP.
  • Impact: A shortage of PLP disrupts various proteins and enzymes that rely on it for function. Because PLP is critical for neurotransmitter metabolism, its deficiency is believed to be the direct cause of the seizures characteristic of this condition.

Genomic Location

The PNPO gene is located on chromosome 17.

Frequently Asked Questions

Standard over-the-counter vitamin B6 supplements usually contain pyridoxine or pyridoxamine, which the body cannot effectively convert into the active form in PNPO deficiency. Patients require specific prescription formulations of pyridoxal phosphate (PLP), which is the active form of the vitamin that bypasses the defective enzyme pathway to support neurotransmitter function.
When treatment with pyridoxal phosphate is initiated promptly, often within the first few weeks of life, many infants can achieve normal or near-normal developmental milestones and cognitive function. However, delays in diagnosis and treatment can lead to permanent neurological damage, including intellectual disability, movement disorders, and persistent seizure activity.
Diagnosis typically begins with a clinical evaluation of seizure onset shortly after birth, followed by a trial of pyridoxal phosphate (PLP) administration. If the seizures resolve or significantly improve after PLP treatment, the diagnosis is strongly suspected. Genetic testing for variants in the PNPO gene is then performed to confirm the diagnosis and rule out other causes of neonatal seizures.
PNPO deficiency is a lifelong condition, but it is not inherently progressive if managed correctly. The primary goal is to maintain adequate levels of pyridoxal phosphate to prevent seizures and support brain development. Dosage may need to be adjusted as the child grows, and regular monitoring of seizure activity and developmental progress is necessary to ensure the treatment remains effective.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ